JNJ0966 is a novel, potent and highly selective allosteric inhibitor of MMP-9 (matrix metalloproteinase-9) zymogen with an IC50 of 440 nM.

SB-3CT (SB 3CT) is a non-selective and covalent inhibitor of gelatinases/matrix metalloproteinase (MMP) with potential antineoplastic activity.

Batimastat (formerly known as BB-94), a synthetic hydroxamate analog and an anticancer drug developed by Laurie Hines of British Biotech, is a broad spectrum inhibitor of matrix metalloprotease (MMP) with potential antitumor activity.

TAPI-1 is an ADAM17/TACE (TNF-α-converting enzyme) inhibitor with the potential to be used as a therapeutic agent for kidney injury.

MMP-9-IN-1 is a novel, potent and selective matrix metalloproteinase-9 (MMP-9) inhibitor that is able to inhibit tumor growth and metastasis by reducing cell migration and proliferation.

NSC 405020 (NSC405020; NSC-405020) is a novel small molecule inhibitor of MT1-MMP (Membrane type-1 matrix metalloproteinase) that targets the noncatalytic domain of MMP with potential antineoplastic activity.

Ilomastat (GM-6001; GM6001; Galardin), a member of the hydroxamic acid class of reversible metallopeptidase inhibitors with important biological activity, is a potent, synthetic, and broad spectrum matrix metalloprotease (MMP) inhibitor.

Nobiletin (Hexamethoxyflavone; NOB), a naturally occurring flavonoid compound isolated from citrus peels like in tangerine and the Chinese drug chen-pi, has anti-inflammatory and anti-tumor activities.

Marimastat (formerly aslo known as BB2516; BB-2516; TA2516; TA-2516) is an orally bioactive and broad spectrum matrix metalloprotease (MMP) inhibitor with potential anticancer activity.

T-26c is a novel, highly potent and selective inhibitor of matrix metalloproteinase-13 (MMP-13) with an IC50 of 6.75 pM and shows more than 2600-fold selectivity over the other related metalloenzymes.